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ABSTRACT
Stem cell transplantation for myelodysplastic syndrome (MDS) is characterized by high transplant-related
mortality (TRM), especially in older patients and those with more advanced disease. Outcome after peripheral
blood stem cell transplantation (PBSCT) may be superior to earlier results with bone marrow transplantation.
Forty-three patients (aged 12-73 years; median, 49 years) received an HLA-identical sibling donor PBSCT.
Twenty three patients aged <55 years without prohibitive comorbidity received myeloablative total body
irradiation–based conditioning, followed by a T cell–depleted PBSCT and delayed add-back of donor lym-
phocytes. Older patients or those with comorbidities (n  20) received reduced-intensity conditioning and an
unmanipulated PBSCT. Thirty-seven (86%) had advanced disease (refractory anemia with excess blasts [n 
9], refractory anemia with excess blasts in transformation [n  6], acute myelogenous leukemia [n  13], or
treatment-related MDS [n  9]); 6 had low-risk MDS (refractory anemia or refractory anemia with ringed
sideroblasts). The median follow-up was 18 months (range, 5-89 months). Actuarial probabilities of 3-year
overall survival (OS), disease-free survival, relapse, and TRM were 64%, 59%, 26%, and 23%, respectively, for
34 primary MDS patients. The best results were in 19 patients younger than 50 years of age undergoing
myeloablative PBSCT (actuarial probabilities of OS, disease-free survival, relapse, and TRM were 81%, 72%,
22%, and 7%, respectively). Although outcomes for all stages of primary MDS were improved, that for
therapy-related MDS remained dismal, with 11% OS, because of a high relapse rate (89%).
© 2005 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Myelodysplastic syndrome (MDS) is a clonal
ematopoietic disorder characterized by bone mar-
ow dysplasia, cytopenias, and frequent evolution to
cute myelogenous leukemia. The natural history is
xtremely variable; some patients survive many
ears, whereas others die within months after diag-
osis. Factors associated with poor survival include
n advanced French-American-British (FAB) sub-
ype (a high percentage of bone marrow blasts), c
B&MTultiple cytopenias, an abnormal karyotype, prior
ytotoxic therapy, and advanced age. A combination
f marrow blast percentage, number of cytopenias,
nd karyotypic abnormalities has been used to de-
ne an international prognostic scoring system
IPSS) for MDS that can segregate patients into 4
ubgroups with survival ranging from several
onths to several years [1]. Survival according to
isk group is inferior in older patients (60 years)
1]. Patients with therapy-related MDS are not in-
luded in this scoring system, but experience sug-
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6ests that such individuals often have rapidly pro-
ressive, refractory disease.
Treatment approaches for MDS have generally
een unsatisfactory, and allogeneic stem cell trans-
lantation (SCT) remains the only established cura-
ive treatment option. Historically, long-term disease-
ree survival (DFS) has been achieved in 30% to 50%
f patients by using marrow from HLA-identical sib-
ing donors. Success has been limited largely by a high
ate (approximately 40%) of nonrelapse mortality
2-4]. Furthermore, approximately one third of trans-
lant recipients relapse. The risk of recurrence de-
ends on the stage of the disease before transplanta-
ion and the presence of high-risk karyotypic
bnormalities [3,5]. Because they relapse less fre-
uently, patients with refractory anemia (RA) or RA
ith ringed sideroblasts (RARS) have better outcomes
han patients with increased blasts (RA with excess
lasts; RAEB) or those in leukemic transformation
6,7].
Results of SCT for MDS have improved over the
ast decade as a result of better supportive care and the
se of mobilized peripheral blood SCT (PBSCT) in
ieu of bone marrow allografts [8,9]. PBSCT is asso-
iated with faster hematopoietic engraftment, an in-
reased risk of chronic graft-versus-host disease
GVHD), and, perhaps, a more potent graft-versus-
eukemia (GVL) effect. Despite improvements in
ransplantation strategies, older age is consistently a
igh-risk feature for nonrelapse mortality after my-
loablative SCT (MST). Because the median age at
iagnosis of MDS is 70 years, most patients are not
andidates for standard myeloablative conditioning,
nd reduced-intensity conditioning (RIC) regimens
ave been introduced to minimize toxicity and harness
potential GVL effect. Although RIC transplantation
trategies have curative potential, they carry a higher
isk of relapse; this suggests that the conditioning
egimen dose intensity may be important in disease
ontrol [10]. To better deﬁne the risk factors that
ffect outcome, we report our results of a retrospective
tudy of MDS patients who received peripheral blood
tem cell (PBSC) allografts from HLA-identical sib-
ing donors.
ATIENTS AND METHODS
tudy Population
Between May 1997 and June 2004, 43 consecutive
atients (27 male and 16 female) aged 12 to 73 years
median, 49 years) with MDS and an HLA-identical
ibling donor were treated under National Heart,
ung and Blood Institute Institutional Review Board–
pproved protocols. Patients aged 55 years without
rohibitive comorbidity were enrolled into 4 succes-
ive MST protocols (97-H-0099, 99-H-0046, 02-H- m
20111, and 03-H0192) consisting of total body irradi-
tion (TBI)–based conditioning, followed by a T cell–
epleted allograft and scheduled posttransplantation
onor lymphocyte infusions (n  23). Patients ineli-
ible for an ablative transplantation because of age or
oor health were enrolled into 3 successive RIC pro-
ocols (97-H-0042, 99-H-0050, and 01-H-0162) that
onsisted of a ﬂudarabine-based conditioning regimen
ollowed by a T cell–replete allograft (n  20).
Table 1 outlines patient characteristics and trans-
lantation procedures. All diagnoses were classiﬁed
ccording to FAB criteria [11]. There were no patients
ith chronic myelomonocytic leukemia. All patients
ere cytopenic in at least 2 cell lineages. Overall, 7
16%) patients fulﬁlled the criteria for RA/RARS, 14
33%) had RAEB, 9 (21%) had RAEB in transforma-
ion, and 13 (30%) had evidence of transformation to
cute myelogenous leukemia before transplantation.
n 34 (79%) patients, MDS arose de novo, whereas 9
21%) patients had previously received chemotherapy,
adiation, or both. By IPSS cytogenetic criteria, 14
atients (32%) had a high-risk karyotype (chromo-
ome 7 or complex abnormalities), 20 patients (47%)
ad a low-risk karyotype (normal, -Y, 5q-, or 20q-),
nd 9 (21%) patients had a intermediate-risk karyo-
ype (all other abnormalities). By overall IPSS score,
o patients were considered low risk, 8 (19%) patients
ere intermediate 1, 7 (16%) patients were interme-
iate 2, and 28 (65%) patients were high risk. Six
14%) had received cytoreductive chemotherapy be-
ore transplantation without achieving a remission.
reparative Regimen
The myeloablative preparative regimen consisted
f either fractionated TBI (13.6 Gy) and cyclophos-
hamide (120 mg/kg) or fractionated TBI (12.0 Gy),
yclophosphamide (120 mg/kg), and ﬂudarabine (125
g/m2). The RIC regimens used ﬂudarabine (125-
80 mg/m2) and 1 of the following alkylating agents:
yclophosphamide (120 mg/kg), melphalan (140 mg/
2), or infusional busulfan (6.4 mg/kg).
BSC Collection and Processing
Donors received granulocyte colony-stimulating
actor 10 g/kg/d subcutaneously. Mobilized PBSCs
ere collected by leukapheresis on day 5 and again on
ays 6 and 7 if necessary to obtain a target dose of
ore than 5  106 CD34 cells per kilogram of the
ecipient’s weight. T-cell depletion was performed on
ll MSTs by using 1 of 2 CD34 selection methods.
he Ceprate T-cell depletion system (CellPro, Both-
ll, WA), which used combined CD34-positive and
D2-negative selection by immunoabsorption, was
sed in the ﬁrst cohort of patients (protocol 97-H-
099). Subsequent protocols used the Isolex 300i im-
unomagnetic cell separation system, version 2.5
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BBaxter, Deerﬁeld, IL), with combined CD34-positive
nd T cell–negative selection by using a cocktail of
nti-CD2, anti-CD6, and anti-CD7, as previously de-
cribed [12]. Infused T-cell doses were 0.2 to 1.0 
05 CD3 cells per kilogram of recipient weight. After
IC transplantations, patients received either an un-
anipulated PBSCT (protocols 97-H-0042 and 99-
-0050; n 10) or an allograft selectively depleted of
lloreacting T cells (infused T-cell doses of 0.5 to 5.9
108 CD3 cells per kilogram recipient weight; pro-
ocol 01-H-0162; n  10) [13].
osttransplantation Management
MST patients received cyclosporine alone as post-
ransplantation immunosuppression, starting either
n day 4 (n  12) or day 44 (these patients re-
able 1. Clinical and Transplant Characteristics of MDS Patients
Variable All Patients (n  43)
ge
Median, y (range) 49 (12–73)
<50 y 22
>50 y 21
ex
Male 27 (63%)
Female 16 (37%)
AB subtype
RA/RARS 7 (16%)
RAEB 14 (33%)
RAEB-T 9 (21%)
AML 13 (30%)
ytogenetic risk†
Low 20 (47%)
Intermediate 9 (21%)
High 14 (32%)
PSS
Low (0) 0 (0%)
Intermediate 1 (0.5–1) 8 (19%)
Intermediate 2 (1.5–2) 7 (16%)
High (>2) 28 (65%)
tiology of MDS
Idiopathic 34 (79%)
Prior cytotoxic 9 (21%)
lasts at transplantation
<10% 18 (42%)
>10% 25 (58%)
reparative regimen
TBI/Cy 11 (26%)
TBI/Cy/Flu 12 (28%)
Flu/Cy‡ 12 (28%)
Flu/Mel‡ 4 (9%)
Flu/Bu‡ 4 (9%)
VHD
Acute (grade >II) 17 (39%)
Chronic (any) 24 (65%)
None 16 (37%)
BI indicates total body irradiation; Cy, cyclophosphamide; Flu, ﬂ
tion; NS, not signiﬁcant.
RA/RARS versus other.
Low indicates normal, -y, 5q-, or 20q-; high, chromosome 7 abnorm
abnormalities.
Ten patients received selectively depleted SCT (see “Patients andeived donor lymphocyte infusions on day 45; n  p
B&MT1). MST patients received planned infusions of cryo-
reserved donor peripheral blood mononuclear cells
n day 45 and day 100 at a T-cell dose of 1  107
D3 cells per kilogram and 5  107 CD3 cells per
ilogram, respectively, in the absence of GVHD. RIC
atients received cyclosporine starting on day 5,
ither alone (n  17) or with mycophenolate mofetil
n  3). Immunosuppression was tapered off by day
100 in the absence of GVHD. Patients with disease
rogression or donor T-cell chimerism of 100%
fter withdrawal of immunosuppression received
raded donor lymphocyte infusions at 4-week inter-
als until 100% donor T-cell chimerism or disease
egression was achieved. All patients received ﬂucon-
zole for antifungal prophylaxis, acyclovir for antiviral
rophylaxis, and trimethoprim/sulfamethoxazole as
MST (n  23) RIC (n  20) P Value
40 (12–55) 61 (28–73) <.001
19 3
4 17
13 (57%) 14 (70%) NS
10 (43%) 6 (30%)
7 (30%) 0 (0%) .01*
4 (17%) 10 (50%)
6 (26%) 3 (15%)
6 (26%) 7 (35%)
12 (52%) 8 (40%) NS
5 (22%) 4 (20%)
6 (26%) 8 (40%)
0 (0%) 0 (0%) NS
5 (22%) 3 (15%)
3 (13%) 4 (20%)
15 (65%) 13 (65%)
19 (83%) 15 (75%) NS
4 (17%) 5 (25%)
9 (39%) 9 (45%) NS
14 (61%) 11 (55%)
11 (48%) <.001
12 (52%)
12 (60%)
4 (20%)
4 (20%)
10 (43%) 7 (35%) NS
16 (73%) 8 (53%)
6 (26%) 10 (50%)
ne; Mel, melphalan; Bu, busulfan; RAEB-T, RAEB in transforma-
and complex (3) abnormalities; and intermediate, all other clonal
ds”).udarabi
alitiesneumocystis prophylaxis. Blood was tested weekly
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6or cytomegalovirus pp65 antigen until day 100, and
anciclovir was initiated when there was evidence of
ytomegalovirus reactivation.
tatistical Analysis
Summary statistics—such as proportions, means,
tandard deviations, 95% conﬁdence intervals (CIs),
edians, and ranges—were used to describe the pa-
ient characteristics, pretransplantation variables, and
ransplantation outcomes. Differences in pretrans-
lantation characteristics between treatment groups
MST versus RIC) were compared by using Fisher
xact tests. Standard techniques in survival analysis,
ncluding Kaplan-Meier estimates, were used to esti-
ate the time-to-event distributions of overall sur-
ival (OS), DFS, transplant-related mortality (TRM),
nd relapse risk. Log-rank analysis was used to com-
are survival curves. The following factors were ana-
yzed with regard to outcomes: recipient age and sex,
AB classiﬁcation, cytogenetic subgroup, IPSS score,
arrow blast percentage, etiology (de novo versus
rior cytotoxic therapy), transplant type (MST versus
IC), CD34 dose, and the development of acute or
hronic GVHD. Univariate and multivariate analysis
f prognostic factors were performed by using a pro-
ortional hazards Cox regression model.
ESULTS
atient and Transplant Characteristics
Forty-three patients aged 12 to 73 years (median,
9 years) received a PBSCT from a matched related
ibling donor. Patients aged 55 years without pro-
ibitive comorbidity received myeloablative condi-
ioning that consisted of TBI and cyclophosphamide
with or without ﬂudarabine), followed by a T cell–
epleted allograft and scheduled posttransplantation
onor lymphocyte infusions (MST group; n  23).
atients ineligible for an ablative transplantation be-
ause of age or poor health received RIC (ﬂudarabine
nd cyclophosphamide, melphalan, or busulfan) fol-
owed by a T cell–replete allograft (RIC group; n 
0). A summary of the patient characteristics is shown
n Table 1. More than 80% of patients had advanced
isease by IPSS scoring: either high (65%) or inter-
ediate 2 (16%). Furthermore, 8 patients (21%) had
reatment-related MDS after exposure to cytotoxic
herapy, and 14 patients (32%) had high-risk cytoge-
etics characterized by chromosome 7 or complex
aryotypic abnormalities (including 8 of the 8 cases of
reatment-related MDS). Patients receiving RIC allo-
rafts were older (median age, 61 versus 40 years; P 
001) and had more aggressive disease (RA/RARS in
% versus 30%; P  .01). Six (14%) patients given
ytoreductive chemotherapy before transplantation
eceived RIC transplants. r
22elapse and TRM
Seven patients died of transplant-related compli-
ations after a median interval of 163 days (range,
2-319 days). The cumulative probability of TRM for
he entire group of patients at 3 years was 22%. A
rend toward higher TRM in older patients (49
ears of age) was seen (41% versus 11%; P  .064).
his occurred even though approximately 80% of
lder patients underwent RIC transplantations. There
as no association between TRM and any other dis-
ase or transplant characteristic.
Relapses occurred in 14 patients after a median
nterval of 160 days (range, 21-289 days). The cumu-
ative probability of relapse for the entire patient
roup at 3 years was 41%. The strongest factor affect-
ng relapse risk was the etiology of MDS (the relapse
ate was 25% in de novo MDS and 89% in treatment-
igure 1. Effect of disease type on transplantation outcomes. A,
verall survival (OS). B, Relapse-free survival (RFS). C, Relapse.
isease types include RA/RAEB (n  15), refractory anemia with
xcess blasts in transformation (RAEB-t)/secondary AML [sAML]
n  19), and treatment-related MDS (n  9).elated MDS; relative risk [RR], 6.37; 95% CI, 4.91-
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B4.48; Figure 1). Other factors predictive of an in-
reased relapse risk in univariate analysis included a
igh IPSS score (RR, 4.9; 95% CI, 1.2-7.9), older age
RR, 3.1; 95% CI, 1.1-8.8), absence of GVHD (RR,
.9; 95% CI, 1.1-11.3), and high-risk cytogenetics
RR, 2.8; 95% CI, 1.1-11.7; Table 2). In multivariate
nalysis, only treatment-related etiology (RR, 7.0;
5% CI, 2.9-132.0) and absence of GVHD (RR, 4.5;
5% CI, 1.4-14.6) remained independent predictors
f relapse risk. The effect of GVHD on the risk of
elapse is depicted in Figure 2.
S and DFS
At a median follow-up of 18 months (range, 5-89
onths), 25 patients were alive with an actuarial OS
nd relapse-free survival of 54% and 48%, respec-
ively. Patients with primary MDS fared signiﬁcantly
etter than those with treatment-related disease, with
S and DFS of 66% versus 11% (P  .002) and 59%
ersus 11% (P  .003), respectively (Figure 1). In
atients with primary MDS, OS and DFS were 74%
able 2. Survival, Transplant-Related Mortality, and Relapse Risk: Un
Variable No. Patients
OS (%),
mean  SD
ll patients 43 54  7
Primary 34 66  9
Treatment related 9 11  10
P value .002
DS subtype
RA/RARS 7 100
RAEB 14 41  14
RAEB-T/sAML 22 44  12
P value .046
ytogenetic risk
High risk 14 29  13
Other 29 65  10
P value .002
PSS
High risk 28 40  11
Other 15 73  11
P value .071
lasts*
<10% 18 75  11
>10% 25 40  10
P value .048
ransplant type
MST 23 66  11
RIC 20 39  12
P value .02
VHD
Acute or chronic 27 62  10
None 16 36  15
P value .106
ge
<50 y 22 75  10
>50 y 21 28  11
P value .003
S indicates overall survival; RFS, relapse-free survival; TRM, tra
reduced-intensity ﬂudarabine-based conditioning; RAEB-T, RA
Pretransplantation blast counts.nd 68% in patients with RA or RAEB and 55% and g
B&MT0% in patients with evidence of transformation to
cute myelogenous leukemia (20% blasts). In pa-
ients younger than 50 years of age who received
tandard myeloablative conditioning (n 19), OS and
FS were 81% and 72%, respectively (Figure 3). The
uperior outcomes of this subgroup were due to both
ow TRM (7%) and relapse (22%). In univariate anal-
e Analysis
RFS (%),
mean  SD
TRM (%),
mean  SD
Relapse Risk (%),
mean  SD
48  8 22  8 41  8
59  9 25  8 25  8
11  10 0 89  10
.003 .286 .001
86  13 0 14  13
41  14 33  14 38  16
40  11 26  13 51  12
.127 .155 .083
31  13 16  11 63  15
57  10 21  9 31  9
.041 .697 .038
37  10 26  12 53  11
67  12 20  10 17  11
.068 .94 .019
69  12 11  7 30  13
35  10 32  12 47  11
.025 .325 .089
59  11 17  9 28  10
37  11 27  12 58  13
.059 .224 .069
54  10 22  9 63  15
42  13 17  11 29  9
.122 .887 .027
67  10 11  7 25  10
27  11 41  16 61  13
.012 .064 .033
t-related mortality; MST, standard TBI-based conditioning; RIC,
transformation; sAML, secondary AML.
igure 2. Effect of GVHD on relapse after transplantation. Relapse
isk is shown by the presence (n  27) or absence (n  16) ofivariat
nsplan
EB inraft-versus-host disease (acute and/or chronic).
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6sis, statistically signiﬁcant risk factors for treatment
ailure included treatment-related MDS (RR, 3.4;
5% CI, 1.8-20.4), age 49 years (RR, 3.0; 95% CI,
.3-7.5), presence of at least 10% bone marrow blasts
t the time of transplantation (RR, 3.0; 95% CI, 1.1-
.3), and presence of high risk cytogenetics (RR, 2.4;
5% CI, 1.0-7.9; Table 2). In multivariate analysis,
nly treatment-related etiology remained a signiﬁcant
ndependent predictor of lower DFS (RR, 2.8; 95%
I, 1.1-7.6).
ISCUSSION
This retrospective study demonstrated that
BSCT from HLA-identical siblings was associated
ith improved transplantation outcomes in patients
ith MDS compared with prior studies [2-4], includ-
ng patients with advanced disease and those in leukemic
ransformation. In contrast, patients with therapy-
elated MDS did not derive a similar beneﬁt from
BSCT. Of the 8 patients in our study with a history
f cytotoxic chemotherapy (8 with chromosome 7 or
omplex karyotypic abnormalities), there was only 1
ong-term survivor. The remaining patients all re-
apsed rapidly at a median time of 135 days after
ransplantation. These results are similar to other re-
orts showing inferior outcomes for patients with
reatment-related MDS [14,15].
Our study population represented a high-risk co-
igure 3. Transplantation outcomes in patients younger than 50 y
urvival (OS). B, Relapse-free survival (RFS). C, Transplant-relatedort that included patients with advanced age and G
24rogressed disease status (IPSS score: 19%, interme-
iate 1; 16%, intermediate 2; and 65%, high). In
atients with primary MDS, we observed 3-year OS,
FS, relapse, and TRM rates of 66%, 59%, 25%, and
5%, respectively. This compares favorably to the
0% to 40% DFS reported in several bone marrow
ransplantation (BMT) series [2-4] or large BMT reg-
stry [7] trials. A more contemporary series from the
eattle group [16] used targeted busulfan and cyclo-
hosphamide conditioning in 42 recipients of HLA-
dentical sibling marrow (n  19) or PBSCT (n  23)
llografts and reported a 56% relapse-free survival
ate at 3 years. However, the disease status of the study
opulation was less advanced than in most series (63%
A/RARS and 71% low or intermediate 1 IPSS
core), and the DFS rate of more advanced patients
33%-45%) was more comparable to that in other
ublished results.
The superiority of PBSCT over BMT for MDS
as demonstrated in a recent large multicenter retro-
pective comparison performed by the European
lood and Marrow Transplantation Group [9]. Al-
hough follow-up in this study was relatively short
median, 12 months), recipients of PBSCT had a su-
erior 2-year relapse-free survival (50% versus 39%)
hat was due to both lower TRM and relapse risk. The
dvantage of PBSCT over BMT most likely derives
rom its association with faster hematopoietic and im-
unologic recovery [17]. Although rates of chronic
age who underwent standard TBI-based conditioning. A, Overall
lity (TRM). D, Relapse.ears ofVHD seem higher with PBSCT, GVL effects may
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Blso be more potent, thus leading to reduced relapse
ates in high-risk hematologic malignancies [9,18].
The curative potential of SCT is believed to result
rom a combination of the cytoreductive properties of
he preparative regimen and the immunotherapeutic
roperties of allogeneic lymphocytes. The relative im-
ortance of conditioning regimen intensity and GVL
nMDS remains unclear. A recent study from de Lima
t al. [10] concluded that preparative regimen inten-
ity is a major determinant of disease control after
ransplantation. The study compared a myeloablative
nd immunoablative regimen that consisted of ﬂu-
arabine and melphalan (140-180 mg/m2) with a mod-
stly myelosuppressive and immunosuppressive regi-
en that consisted of ﬂudarabine, cytarabine, and
darubicin (FAI). Although long-term survival was
imilar with the 2 regimens (approximately 30%), the
elapse risk was signiﬁcantly worse in the FAI group
61% versus 30%). Although the degree of cytoreduc-
ion may have played a role in preventing relapse, it
ay not be the only important variable. A careful
eview of this study demonstrates some interesting
ifferences between the groups. The FAI group dem-
nstrated slower donor immune recovery, which led
o higher degrees of mixed chimerism and signiﬁ-
antly more graft failure (20% versus 3%). Further-
ore, the FAI group was characterized by more bone
arrow allografts (84% versus 42%), less use of alter-
ative donors (19% versus 60%), and a lower inci-
ence of acute and chronic GVHD. Given the known
orrelation of antitumor response with full donor chi-
erism [19,20] and GVHD [21], GVL potency may
e an alternative explanation for the ﬁndings of this
tudy.
The relative importance of GVL in controlling
DS after SCT is also supported by our ﬁndings.
ultivariate analysis demonstrated a clear inverse cor-
elation between the presence of GVHD and relapse
isk: this is evidence for a GVL effect in MDS. Two
ther studies of allogeneic SCT for MDS make sim-
lar conclusions [22,23]. Although recipients of MST
n our study had superior DFS compared with recip-
ents of RIC transplants (59% versus 37%), we did not
nd a signiﬁcant association between conditioning
ntensity (MST versus RIC groups) and relapse risk in
nivariate or multivariate analysis. The characteristics
f the RIC group (older age, more advance disease,
nd less GVHD) may have accounted for some of the
ifferences in outcomes.
The use of RIC regimens makes it possible to offer
urative therapy to patients who are not candidates for
tandard SCT because of older age and comorbidities.
lthough not optimal, almost 40% of patients
chieved long-term survival after RIC transplanta-
ion—a reasonable result in light of the fact that all
atients had high-risk features before SCT (excess
lasts, high-risk cytogenetics, or prior cytotoxic ther-
B&MTpy). Despite the use of RIC regimens, TRM contin-
es to be problematic for older individuals (47% ver-
us 12% for age 50 and 50 years, respectively) and
eads to inferior survival in these patients (43% versus
1% survival in primary MDS patients aged 50 and
50 years, respectively; Figure 4).
In summary, PBSCT from HLA-identical siblings
ffers superior outcomes for primary MDS patients,
articularly for patients younger than 50 years of age.
he use of PBSCT has signiﬁcantly reduced TRM
nd improved GVL in patients with advanced disease.
urther progress in the use of allogeneic SCT in MDS
hould focus on decreasing nonrelapse mortality rates
n older individuals and further improving GVL efﬁ-
acy in patients with high-risk disease.
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